Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in Histopathology Retrieve available abstracts of 76 articles: HTML format

Single Articles

September 2024
1. WONG CJW, Md Nasir ND, Koh VCY, Campbell F, et al
   Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast.
   Histopathology. 2024;85:510-520.
   PubMed     Abstract available
   
   
   
2. BATRA H, Bose PSC, Ding Y, Dai A, et al
   MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers.
   Histopathology. 2024;85:503-509.
   PubMed     Abstract available
   
   
   
3. TURASHVILI G
   Nonneoplastic and neoplastic sclerosing lesions of the breast.
   Histopathology. 2024;85:383-396.
   PubMed     Abstract available
   
   
   
4. GRABENSTETTER A, Brennan SB, Jochelson MS, Brogi E, et al
   Radial sclerosing lesions found on core needle biopsy: excision can be safely avoided.
   Histopathology. 2024;85:397-404.
   PubMed     Abstract available
   
   
   
5. ELLIS I, Webster F, Allison KH, Dang C, et al
   Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR).
   Histopathology. 2024;85:418-436.
   PubMed     Abstract available
   
   
   August 2024
6. ZWAGER MC, Yu S, Buikema HJ, de Bock GH, et al
   Advancing Ki67 hotspot detection in breast cancer: a comparative analysis of automated digital image analysis algorithms.
   Histopathology. 2024 Aug 5. doi: 10.1111/his.15294.
   PubMed     Abstract available
   
   
   July 2024
7. BANNIER PA, Broeckx G, Herpin L, Dubois R, et al
   Development of a deep-learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2-low cases.
   Histopathology. 2024 Jul 14. doi: 10.1111/his.15274.
   PubMed     Abstract available
   
   
   
8. TOZBIKIAN G, Bui MM, Hicks DG, Jaffer S, et al
   Best practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists.
   Histopathology. 2024 Jul 8. doi: 10.1111/his.15275.
   PubMed     Abstract available
   
   
   
9. ZHANG H, Finkelman BS, Ettel MG, Velez MJ, et al
   HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
   Histopathology. 2024;85:3-19.
   PubMed     Abstract available
   
   
   June 2024
10. LASHEN AG, Toss M, Miligy I, Rewcastle E, et al
    Nottingham prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: a validation study.
    Histopathology. 2024 Jun 13. doi: 10.1111/his.15234.
    PubMed     Abstract available
    
    
    
11. MILIGY IM, Awasthi R, Mir Y, Khurana A, et al
    Morphological and molecular changes of oestrogen receptor-positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study.
    Histopathology. 2024 Jun 7. doi: 10.1111/his.15238.
    PubMed     Abstract available
    
    
    
12. LAOKULRATH N, Gudi M, Salahuddin SA, Chong APY, et al
    Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges.
    Histopathology. 2024 Jun 6. doi: 10.1111/his.15213.
    PubMed     Abstract available
    
    
    
13. BOSSUYT V, Provenzano E, Symmans WF, Webster F, et al
    A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;84:1111-1129.
    PubMed     Abstract available
    
    
    May 2024
14. LI J, Dong P, Wang X, Zhang J, et al
    Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
    Histopathology. 2024 May 15. doi: 10.1111/his.15205.
    PubMed     Abstract available
    
    
    
15. HUANG CY, Chang RF, Lin CY, Hsieh MS, et al
    Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
    Histopathology. 2024;84:983-1002.
    PubMed     Abstract available
    
    
    April 2024
16. BADR NM, Zaakouk M, Zhang Q, Kearns D, et al
    Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Histopathology. 2024 Apr 23. doi: 10.1111/his.15193.
    PubMed     Abstract available
    
    
    
17. LI JJX, Ni SYB, Tsang JYS, Chan WY, et al
    Neutrophil-lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy.
    Histopathology. 2024;84:810-821.
    PubMed     Abstract available
    
    
    
18. ALKHAYYAT R, Abbas A, Quinn CM, Rakha EA, et al
    Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
    Histopathology. 2024;84:723-741.
    PubMed     Abstract available
    
    
    
19. AZAM AS, Tsang YW, Thirlwall J, Kimani PK, et al
    Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
    Histopathology. 2024;84:847-862.
    PubMed     Abstract available
    
    
    March 2024
20. LY A, Garcia V, Blenman KRM, Ehinger A, et al
    Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research.
    Histopathology. 2024 Mar 3. doi: 10.1111/his.15140.
    PubMed     Abstract available
    
    
    January 2024
21. LUI JW, Tsang JY, Li J, Ko CW, et al
    TRPS1 is a promising marker for all subtypes of breast cancer.
    Histopathology. 2024 Jan 3. doi: 10.1111/his.15126.
    PubMed     Abstract available
    
    
    
22. SCHWARTZ CJ, Krings G, Chen YY
    Malignant phyllodes tumour with lymph node metastasis: a diagnostic conundrum resolved by next generation DNA sequencing.
    Histopathology. 2024;84:409-411.
    PubMed     Abstract available
    
    
    December 2023
23. TAN PH, Mihir G, Laokulrath N, Rakha E, et al
    Practical approach to scoring HER2 immunohistochemistry in breast cancer in the wake of updated guidelines.
    Histopathology. 2023 Dec 12. doi: 10.1111/his.15117.
    PubMed    
    
    
    
24. BOYRAZ B, Sgroi DC, Iafrate AJ, Lerwill MF, et al
    Atypical cystic hypersecretory lesions of the breast commonly harbour TP53 alterations.
    Histopathology. 2023;83:989-993.
    PubMed     Abstract available
    
    
    September 2023
25. LEE AHS, Toss MS, James JJ, Hodi Z, et al
    Preoperative diagnosis of ductal carcinoma in situ of the breast over a 24-year period.
    Histopathology. 2023;83:435-442.
    PubMed     Abstract available
    
    
    
26. RAKHA EA, Adebayo LA, Abbas A, Hodi Z, et al
    Second opinion (external specialist referral) practice of breast pathology: the Nottingham experience.
    Histopathology. 2023;83:394-405.
    PubMed     Abstract available
    
    
    
27. GHANNAM SF, Rutland CS, Allegrucci C, Mongan NP, et al
    Encapsulated papillary carcinoma of the breast: does it have a native basement membrane?
    Histopathology. 2023;83:376-393.
    PubMed     Abstract available
    
    
    
28. AIYER KTS, Kroon LJ, van Leenders GJLH
    Impact of comedonecrosis on prostate cancer outcome: a systematic review.
    Histopathology. 2023;83:339-347.
    PubMed     Abstract available
    
    
    
29. JORNS JM, Farooq A, Puzyrenko A, Jarzembowski J, et al
    Giant juvenile fibroadenomas with and without prominent pseudoangiomatous stromal hyperplasia (PASH)-like change: clinicopathological and molecular characteristics.
    Histopathology. 2023;83:357-365.
    PubMed     Abstract available
    
    
    August 2023
30. NIELSEN TO, Leung SCY, Riaz N, Mulligan AM, et al
    Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial.
    Histopathology. 2023 Aug 23. doi: 10.1111/his.15032.
    PubMed     Abstract available
    
    
    
31. LEWIS G, Fong N, Gjeorgjievski SG, Li XB, et al
    Low-grade adenosquamous carcinoma of the breast: a clinical, morphological and immunohistochemical analysis of 25 patients.
    Histopathology. 2023;83:252-263.
    PubMed     Abstract available
    
    
    July 2023
32. THORNE H, Devereux L, Li J, Alsop K, et al
    BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
    Histopathology. 2023;83:91-103.
    PubMed     Abstract available
    
    
    June 2023
33. GOUGH M, Liu C, Srinivasan B, Wilkinson L, et al
    Improved concordance of challenging human epidermal growth factor receptor 2 dual in-situ hybridisation cases with the use of a digital image analysis algorithm in breast cancer.
    Histopathology. 2023 Jun 27. doi: 10.1111/his.15000.
    PubMed     Abstract available
    
    
    May 2023
34. HARTER D, O'Connor SM, Hertel JD, Calhoun BC, et al
    Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy.
    Histopathology. 2023 May 31. doi: 10.1111/his.14966.
    PubMed     Abstract available
    
    
    
35. LASHEN AG, Toss MS, Wootton L, Green AR, et al
    Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer.
    Histopathology. 2023 May 24. doi: 10.1111/his.14960.
    PubMed     Abstract available
    
    
    April 2023
36. ZENG L, Koh VCY, Chen XY, Tan PH, et al
    Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathological parameters.
    Histopathology. 2023;82:779-788.
    PubMed     Abstract available
    
    
    
37. LASHEN A, Toss MS, Fadhil W, Oni G, et al
    Evaluation oncotype DX((R)) 21-gene recurrence score and clinicopathological parameters: a single institutional experience.
    Histopathology. 2023;82:755-766.
    PubMed     Abstract available
    
    
    
38. MD NASIR ND, Koh VCY, Cree IA, Ruiz BII, et al
    Phyllodes tumour evidence gaps mapped from the 5th edition of the WHO classification of tumours of the breast.
    Histopathology. 2023;82:704-712.
    PubMed     Abstract available
    
    
    
39. CHARTIER S, Brochard C, Martinat C, Coussy F, et al
    TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas.
    Histopathology. 2023;82:664-671.
    PubMed     Abstract available
    
    
    February 2023
40. IBRAHIM A, Toss MS, Atallah NM, Al Saleem M, et al
    Combined proliferation and apoptosis index provides better risk stratification in breast cancer.
    Histopathology. 2023 Feb 13. doi: 10.1111/his.14887.
    PubMed     Abstract available
    
    
    
41. SODE M, Thagaard J, Eriksen JO, Laenkholm AV, et al
    Digital image analysis and assisted reading of the HER2 score display reduced concordance - Pitfalls in the categorization of HER2-low breast cancer.
    Histopathology. 2023 Feb 3. doi: 10.1111/his.14877.
    PubMed     Abstract available
    
    
    
42. LAI BS, Tsang JY, Li JJ, Poon IK, et al
    Anatomical site and size of sentinel lymph node metastasis predicted additional axillary tumour burden and breast cancer survival.
    Histopathology. 2023 Feb 1. doi: 10.1111/his.14875.
    PubMed     Abstract available
    
    
    January 2023
43. ELLIS IO, Rakha EA, Tse GM, Tan PH, et al
    An international unified approach to reporting and grading invasive breast cancer. An overview of the International Collaboration on Cancer Reporting (ICCR) initiative.
    Histopathology. 2023;82:189-197.
    PubMed     Abstract available
    
    
    
44. RAKHA EA, Tse GM, Quinn CM
    An update on the pathological classification of breast cancer.
    Histopathology. 2023;82:5-16.
    PubMed     Abstract available
    
    
    
45. CHAN RC, To CKC, Cheng KCT, Yoshikazu T, et al
    Artificial intelligence in breast cancer histopathology.
    Histopathology. 2023;82:198-210.
    PubMed     Abstract available
    
    
    
46. PROVENZANO E, Shaaban AM
    Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer.
    Histopathology. 2023;82:170-188.
    PubMed     Abstract available
    
    
    
47. SOKOLOVA A, Johnstone KJ, McCart Reed AE, Simpson PT, et al
    Hereditary breast cancer: syndromes, tumour pathology and molecular testing.
    Histopathology. 2023;82:70-82.
    PubMed     Abstract available
    
    
    
48. NOURIEH M, Vibert R, Saint-Ghislain M, Cyrta J, et al
    Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction.
    Histopathology. 2023;82:162-169.
    PubMed     Abstract available
    
    
    
49. TAN BY, Fox SB, Lakhani SR, Tan PH, et al
    Survey of recurrent diagnostic challenges in breast phyllodes tumours.
    Histopathology. 2023;82:95-105.
    PubMed     Abstract available
    
    
    
50. TSANG JY, Tse GM
    Update on triple-negative breast cancers - highlighting subtyping update and treatment implication.
    Histopathology. 2023;82:17-35.
    PubMed     Abstract available
    
    
    
51. LI JJX, Tse GM
    Marker assessments in ER-positive breast cancers: old markers, new applications?
    Histopathology. 2023;82:218-231.
    PubMed     Abstract available
    
    
    November 2022
52. IBRAHIM A, Toss MS, Makhlouf S, Miligy IM, et al
    Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
    Histopathology. 2022 Nov 8. doi: 10.1111/his.14837.
    PubMed     Abstract available
    
    
    
53. XU B, Viswanathan K, Umrau K, Al-Ameri TAD, et al
    Secretory carcinoma of the salivary gland: a multi-institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors.
    Histopathology. 2022;81:670-679.
    PubMed     Abstract available
    
    
    October 2022
54. FOX SB, Webster F, Chen CJ, Chua B, et al
    Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2022;81:467-476.
    PubMed     Abstract available
    
    
    September 2022
55. VERNEMMEN AIP, Li X, Roemen GMJM, Speel EM, et al
    Cutaneous metastases of internal malignancies: a single-institution experience.
    Histopathology. 2022;81:329-341.
    PubMed     Abstract available
    
    
    August 2022
56. ATALLAH NM, Toss MS, Green AR, Mongan NP, et al
    Refining the definition of HER2 low class in invasive breast cancer.
    Histopathology. 2022 Aug 28. doi: 10.1111/his.14780.
    PubMed     Abstract available
    
    
    
57. LASHEN A, Toss MS, Green AR, Mongan NP, et al
    Ki67 assessment in invasive luminal breast cancer: A comparative study between different scoring methods.
    Histopathology. 2022 Aug 23. doi: 10.1111/his.14781.
    PubMed     Abstract available
    
    
    
58. OISHI N, Feldman AL
    CA9 expression in breast implant-associated anaplastic large cell lymphoma presenting in a lymph node.
    Histopathology. 2022;81:270-272.
    PubMed    
    
    
    July 2022
59. KATAYAMA A, Starczynski J, Toss MS, Shaaban AM, et al
    The frequency and clinical significance of centromere enumeration probe 17 alterations in HER2 immunohistochemistry-equivocal invasive breast cancer.
    Histopathology. 2022 Jul 25. doi: 10.1111/his.14728.
    PubMed     Abstract available
    
    
    
60. RAKHA E, Tan PH
    Head to head: do neuroendocrine tumours in the breast truly exist?
    Histopathology. 2022;81:2-14.
    PubMed     Abstract available
    
    
    February 2022
61. KATAYAMA A, Toss MS, Parkin M, Sano T, et al
    Nuclear morphology in breast lesions: refining its assessment to improve diagnostic concordance.
    Histopathology. 2022;80:515-528.
    PubMed     Abstract available
    
    
    
62. ABRAHAO-MACHADO LF, Bacchi CE, de Freitas CP, Hornick JL, et al
    Malignant peripheral nerve sheath tumour with multilineage divergent differentiation including a neuroblastic component.
    Histopathology. 2022;80:607-609.
    PubMed    
    
    
    January 2022
63. KHOURY T, Quinn M, Tian W, Yan L, et al
    Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.
    Histopathology. 2022;80:291-303.
    PubMed     Abstract available
    
    
    December 2021
64. LI J, Mi W, Guo Y, Ren X, et al
    Artificial intelligence for histological subtype classification of breast cancer: combining multi-scale feature maps and recurrent attention model.
    Histopathology. 2021 Dec 24. doi: 10.1111/his.14613.
    PubMed     Abstract available
    
    
    
65. MA S, Zhao D, Liu Y, Rohr J, et al
    Some pleomorphic adenomas of the breast share PLAG1 rearrangements with the analogous tumour of the salivary glands.
    Histopathology. 2021;79:1030-1039.
    PubMed     Abstract available
    
    
    November 2021
66. KLARIC KA, Riaz N, Asleh K, Wang XQ, et al
    SOX10 is a highly specific biomarker of basal-like breast cancer.
    Histopathology. 2021 Nov 1. doi: 10.1111/his.14592.
    PubMed     Abstract available
    
    
    October 2021
67. RAKHA E, Mihai R, Abbas A, Bennett R, et al
    Diagnostic concordance of phyllodes tumour of the breast.
    Histopathology. 2021;79:607-618.
    PubMed     Abstract available
    
    
    
68. CAI L, Yan K, Bu H, Yue M, et al
    Improving Ki67 assessment concordance by the use of an artificial intelligence-empowered microscope: a multi-institutional ring study.
    Histopathology. 2021;79:544-555.
    PubMed     Abstract available
    
    
    
69. RAKHA E, Tan PH, Ellis I, Quinn C, et al
    Adenomyoepithelioma of the breast: a proposal for classification.
    Histopathology. 2021;79:465-479.
    PubMed     Abstract available
    
    
    August 2021
70. MANSY M, Wotherspoon AC, El-Sharkawi D, Cunningham D, et al
    Fibrin-associated diffuse large B-cell lymphoma misdiagnosed as breast implant-associated anaplastic large-cell lymphoma.
    Histopathology. 2021;79:269-271.
    PubMed    
    
    
    
71. BODEN ACS, Molin J, Garvin S, West RA, et al
    The human-in-the-loop: an evaluation of pathologists' interaction with artificial intelligence in clinical practice.
    Histopathology. 2021;79:210-218.
    PubMed     Abstract available
    
    
    May 2021
72. MIHAI R, Callagy G, Qassid OL, Loughlin MO, et al
    Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast.
    Histopathology. 2021;78:871-881.
    PubMed     Abstract available
    
    
    April 2021
73. RAKHA EA, Quinn CM, Foschini MP, Munoz Martin M, et al
    Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management.
    Histopathology. 2021;78:759-771.
    PubMed     Abstract available
    
    
    March 2021
74. NOSKE A, Ammann JU, Wagner DC, Denkert C, et al
    A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
    Histopathology. 2021;78:567-577.
    PubMed     Abstract available
    
    
    
75. GHOSSEIN CA, Khimraj A, Dogan S, Xu B, et al
    Metastasis to the thyroid gland: a single-institution 16-year experience.
    Histopathology. 2021;78:508-519.
    PubMed     Abstract available
    
    
    
76. HODA RS, Bowman AS, Zehir A, Razavi P, et al
    Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 te
    Histopathology. 2021;78:498-507.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.